STANDARD BIOTOOLS INC. 8-K

What Happened

• Standard BioTools Inc. (LAB) filed an 8-K on June 18, 2026 reporting results of its June 17, 2026 Annual Meeting. Shareholders elected three Class I directors — Michael Egholm, Ph.D.; Thomas Carey; and Eli Casdin — and approved the company’s 2026 Equity Incentive Plan and an amendment to the Amended and Restated 2017 Employee Stock Purchase Plan (ESPP).
• At the record date (April 24, 2026) the company had 390,368,119 shares outstanding; 335,900,644 votes (≈86.04% of outstanding voting power) were represented at the meeting. The ESPP amendment increases the shares reserved under the ESPP by 1,200,000 shares. The full texts of the 2026 Plan and the amended ESPP are filed as Exhibits 10.1 and 10.2 to the 8-K.

Key Details

• Shares outstanding (Record Date): 390,368,119; votes represented at meeting: 335,900,644 (≈86.04%).
• Director elections (votes for / votes withheld / broker non-votes):
  • Michael Egholm: 236,313,971 / 13,467,627 / 86,119,046
  • Thomas Carey: 227,843,498 / 21,938,100 / 86,119,046
  • Eli Casdin: 234,717,465 / 15,064,133 / 86,119,046
• 2026 Equity Incentive Plan: Approved — votes for 228,342,854; votes against 17,821,911; abstentions 3,616,833; broker non-votes 86,119,046.
• ESPP amendment (increase of 1,200,000 shares): Approved — votes for 237,474,844; votes against 12,276,507; abstentions 30,247; broker non-votes 86,119,046.
• Other votes: Advisory “say-on-pay” approved (For 209,778,412; Against 36,318,595; Abstain 3,684,591); PwC ratified as auditor (For 330,172,606; Against 652,236; Abstain 5,075,802).

Why It Matters

• Approval of the 2026 Equity Incentive Plan and the ESPP amendment increases the pool of shares available for employee and executive awards, which can lead to future dilution of existing shareholders as awards are granted and exercised. The ESPP increase is specifically 1,200,000 additional shares.
• Election of the three Class I directors maintains the company’s board continuity and governance as disclosed. The advisory vote on executive compensation passed, but the level of opposition (over 36 million votes against) is a data point investors may watch for governance engagement and future compensation discussions.